$630 million on the line in Confo and Lilly link-up

2 March 2023

G-protein coupled receptor (GPCR) company Confo Therapeutics has announced a worldwide licensing agreement with US pharma major Eli Lilly (NYSE: LLY) for the Belgian firm’s clinical stage CFTX-1554 and back-up compounds.

CFTX-1554, an inhibitor of the angiotensin II type 2 receptor (AT2R) currently in Phase I development, represents a non-opioid approach to treating neuropathic pain, a condition caused by damage to the nerves outside of the brain and spinal cord, and potentially additional peripheral pain indications.

Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase I.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK